UK Biobank is a large-scale biomedical database and research resource containing genetic, lifestyle and health information from half a million UK participants. The database, which is regularly augmented with additional data, is globally accessible to approved researchers and scientists undertaking vital research into the most common and life-threatening diseases. UK Biobank’s research resource is a major contributor to the advancement of modern medicine and treatment and has enabled several scientific discoveries that improve human health. In this exclusive interview, we speak with Professor Sir Rory Collins FMedSci FRS, Principal Investigator and Chief Executive of UK Biobank, to hear about the achievements to date and the ambitious and unique potential of this exciting project.

To begin, please tell us how UK Biobank came to fruition.

Understanding the factors that influence the onset and trajectory of common life-threatening and disabling conditions presents a critical challenge to medical science. Prospective cohort studies allow the study of individuals over a period of time, and can assess the exposure of individuals to risk factors before the onset and treatment of disease. The UK Medical Research Council and Wellcome Trust decided that they would fund a large prospective cohort at the turn of the century, and after a lot of discussion about what might be done and how it might be done, I was asked in 2005 to deliver the project.

The Lancet kit UK Biobank are using in the COVID sero-prevalence study. Credit UK Biobank

As Principal Investigator and Chief Executive, what are the aims of UK Biobank and how do you envision these aims will be achieved?

The aims are to allow as many researchers globally as possible to apply their expertise and imagination to the de-identified data from the 500,000 altruistic volunteers in as many different ways as possible in order to generate as much knowledge as possible about the causes of many different conditions, with the ultimate aim being to discover ways to prevent and treat those conditions better.

Around 500,000 volunteers have enrolled in the project – what data are being collected from volunteers and how is all this information being used?

At the baseline assessment, all volunteers completed a wide range of measures to ascertain their sociodemographic background, family history and early life exposures, psychosocial and environmental histories, and they also completed in-depth measures of their physical, health and cognitive function. Extensive phenotypic and genotypic information is being collected, including further data obtained from questionnaires, physical measures, sample assays, accelerometry, multimodal imaging, genome-wide genotyping and follow-up assessments conducted over the course of the project for a wide range of health-related outcomes.

High technology blood sample processing. Credit UK Biobank.


What opportunities are available for researchers through UK Biobank?

Uniquely, all of the data (and, indeed, assays of samples) are available to all bona fide researchers (both academic and commercial) worldwide without preferential access for all types of health-related research that is in the public interest. Researchers who fund the enhancement of the resource (e.g., assays of samples) may be given up to a 9-month exclusive access period to use the data that they have generated before those data are made available to all other researchers.

UK Biobank has already led to a wealth of publications in prestigious scientific journals. What do you consider to be UK Biobank’s most important findings to date?

The 500,000 participants were only recruited between 2006 and 2010 and, given that a prospective cohort requires long-term follow-up of health outcomes, the most important findings from UK Biobank will really only emerge over the next 5 to 10 years. Having said that, one important ‘finding’ is that the large investment in UK Biobank made by the Medical Research Council and Wellcome Trust (and others) is already starting to produce dividends in terms of the amount of research that can be conducted rapidly and efficiently by making a very large and very deeply characterised dataset freely available to lots of researchers (as illustrated by the numbers of publications and, increasingly, by their scientific importance). This is a testament to the vision of the funders to invest for the long term and to the altruism of the 500,000 people who volunteered to contribute their information to the resource.

Credit UK Biobank.

 

The project is, of course, made possible by the individuals who have volunteered to take part. How are the key findings and implications for health communicated to the general public?

Participants are informed regularly about the progress of the study (and, particularly, about major initiatives), as well as being invited to participate in additional assessments (such as the ongoing project to image 100,000 of the participants which is now half-way completed). They are also encouraged to review detailed updates on UK Biobank’s website, which are also available to other members of the public. Individual researchers who generate findings based on UK Biobank also put out their own press releases, which are often picked up by the news media.

In the midst of the current pandemic, a better understanding of health and disease is at the forefront of scientific as well as political agendas. What can UK Biobank offer to the COVID-19 response?

The first thing that we did was to put in place much more frequent updates from health record systems on health outcomes occurring among participants, and extended it to access to primary care records for the first time under emergency legal arrangements specifically for COVID-related research, and fast-tracked approval to use the data for such research. Findings about COVID-19 based on these data are already starting to emerge which we hope will help in its control.

At the request of the Wellcome Trust and UK Government, we have recruited about 10,000 of the volunteers, and extended recruitment to a similar number of their children and grandchildren aged over 18 (in order to include people aged less than 50 years), into a study to track the prevalence of previous infection with SARS-CoV-2 (based on a laboratory test for antibodies) throughout the second half of 2020 in different groups within the UK (e.g., different parts of the country, and in people of different age, gender, ethnicity, and socioeconomic status). The results of that study are being made publicly available, as well as being provided to the Government to help guide policy.

The vast UK Biobank freezer in Stockport is so large that several double decker buses could fit in it. Credit UK Biobank.

To conclude, if we may, with some personal reflection, what lessons do you feel we may learn from the COVID-19 pandemic in terms of healthcare in the coming decades?

Let reliable evidence really drive the strategies for the prevention of adverse health outcomes, whether that is due to infectious diseases or chronic diseases (e.g., the pandemic, increasingly in the poorer countries of the world, of tobacco-related deaths and disability that is largely ignored by the media…partly because tobacco is not ‘new’ and partly because the problem is moving away from the richer countries).

W: https://www.ukbiobank.ac.uk/

Twitter: @uk_biobank

Reference
https://doi.org/10.33548/SCIENTIA585

Want to republish our articles?

 

We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more

Creative Commons Licence
(CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.


More articles you may like

Dr Arpan Ashok Patel – Financial Toxicity: Impact on Older Adults with Advanced Cancer

Dr Arpan Ashok Patel – Financial Toxicity: Impact on Older Adults with Advanced Cancer

Dr Arpan Ashok Patel of the University of Rochester School of Medicine and Dentistry is dedicated to better understanding the prevalence and impact of financial toxicity amongst older, more advanced cancer patients. His recent work in this field is the first to analyse real conversations between patients and oncologists in this high-risk group. His findings show that those struggling with financial stability following cancer treatment are more likely to have a lower health-related quality of life, highlighting the need for better screening tools to identify at-risk patients to allow appropriate signposting to support.

Dr Yasuo Koide – Engineering the Path to New Semiconductors

Dr Yasuo Koide – Engineering the Path to New Semiconductors

As fundamental components of our electronic and optical devices, semiconductors are essential to our modern way of life. Dr Yasuo Koide of the National Institute for Material Science in Japan has an extensive history of researching and developing these unique materials. Alongside his colleagues, Dr Koide continues to break through the boundaries of our existing knowledge to create new and exciting technologies.

Dr Victor E. Cabrera – Dairy Brain: A Step Towards Smarter Management in Dairy Farms

Dr Victor E. Cabrera – Dairy Brain: A Step Towards Smarter Management in Dairy Farms

To manage their farms effectively, dairy farmers must base their decisions on real-time and continuous data streams, which collect information about feeding, milking, and an array of other factors. Dairy Brain is a toolkit introduced by Dr Victor E. Cabrera and his colleagues at the University of Wisconsin – Madison, which integrates the data streams collected by different software onto a single platform, and applies the latest algorithms to reveal novel insights. The technology could soon enable farmers and industry professionals to make far better use of the latest techniques in data analysis – and may even lead to new advances in efficiency and sustainability.

Dr Joanne Maki – Preventing Rabies: A Deadly but Neglected Disease

Dr Joanne Maki – Preventing Rabies: A Deadly but Neglected Disease

Rabies is transmitted from animals to humans through the bite of an infected animal, all too often with fatal consequences, particularly in the developing world. Dr Joanne Maki, Technical Director for the Veterinary Public Health Centre at Boehringer-Ingelheim Animal Health, has worked in rabies prevention for 30 years. With extensive background and experience gained in the rabies vaccine industry, Dr Maki shares her perspectives on the call to action to eliminate this deadly zoonotic disease.